Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
for prescribed GLP-1s, ask the prescriber
Early Phase I studies in humans identified 0.025 mg/kg per day (approximately 1.52 mg for an average adult) as an appropriate dose, with measurable tanning observed after just five low doses administered over two weeks [1]
Both the SARC021 (in sarcoma patients) and MAESTRO (in pancreatic cancer patients), phase III trials showed that adding evofosfamide to standard chemotherapy (doxorubicin in soft-tissue sarcoma and gemcitabine in pancreatic cancer) failed to improve overall survival compared to chemotherapy alone (283, 284)
Triple agonist compositions
US$ 21.75
US$ 22.88
US$ 29.58
US$ 20.48
